Oncology Institute CAO files Form 4 with no trades

Oncology Institute, Inc. filed a Form 4 for Chief Administrative Officer Kristin England that shows no reportable insider trades during the period covered.

Rhea-AI Filing Summary

Oncology Institute, Inc. filed a Form 4 for Chief Administrative Officer Kristin England that shows no reportable insider trades during the period covered. The filing lists zero purchases, zero sales, zero derivative exercises, and no gifts, tax withholdings, or restructuring-related transfers.

Key Figures

Shares bought: 0 shares Shares sold: 0 shares Derivative exercises: 0 shares +2 more

5 metrics

Shares bought 0 shares BuyShares in transactionSummary

Shares sold 0 shares SellShares in transactionSummary

Derivative exercises 0 shares ExerciseShares in transactionSummary

Gifts reported 0 shares GiftShares in transactionSummary

Tax withholding dispositions 0 shares TaxWithholdingShares in transactionSummary

Key Terms

Form 4, Chief Administrative Officer, transactionSummary, derivativeSummary

4 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Chief Administrative Officer financial

""officer_title": "Chief Administrative Officer""

transactionSummary financial

""transactionSummary": {"

derivativeSummary financial

""derivativeSummary": [],"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Kristin England (TOI) Form 4 filing report?

The Form 4 for Kristin England at Oncology Institute, Inc. reports no insider stock transactions. It shows zero purchases, zero sales, no option exercises, and no gifts or restructurings during the reported period, indicating no change in her reported holdings.

Did TOI executive Kristin England buy any Oncology Institute shares in this Form 4?

No, this Form 4 shows zero shares purchased by Kristin England. The transaction summary lists no buy transactions and no increase in holdings from open-market or other purchase activity for the reported period.

Did Kristin England sell any TOI stock according to this Form 4?

No, the filing shows zero shares sold. The transaction summary reports no sale transactions, no derivative exercises followed by sales, and no tax-withholding dispositions that would reduce Kristin England’s reported ownership position in this period.

Are there any option or derivative exercises in this TOI Form 4?

No, the Form 4 lists no derivative transactions. ExerciseCount and exerciseShares are both zero, and the derivativeSummary section is empty, indicating no stock option or other derivative exercises during the reporting period.

Does this TOI Form 4 show any gifts or restructuring of Kristin England’s holdings?

No, the transaction summary reports no gifts and no restructuring. GiftCount, giftShares, restructuringCount, and restructuringShares are all zero, indicating no transfers categorized as gifts or entity restructurings in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 09:25 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

England Kristin

(Last) (First) (Middle)

C/O ONCOLOGY INSTITUTE, INC.

18000 STUDEBAKER ROAD, SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Administrative Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Pursuant to a Unanimous Written Consent of the Board of Directors of the Issuer dated April 21, 2026, the reporting person was determined to no longer be an officer of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

	Mark Hueppelsheuser, Attorney-in-fact for Kristin England	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)